Prevádzková marža spoločnosti Knight Therapeutics
Aká je hodnota metriky Prevádzková marža spoločnosti Knight Therapeutics?
Hodnota metriky Prevádzková marža spoločnosti Knight Therapeutics, Inc. je 2.37%
Aká je definícia metriky Prevádzková marža?
Prevádzková marža je pomer prevádzkových výnosov vydelený čistými predajmi a vyjadrený v percentách.
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
Prevádzková marža spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou Knight Therapeutics
Čomu sa venuje spoločnosť Knight Therapeutics?
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Firmy s metrikou prevádzková marža podobnou spoločnosti Knight Therapeutics
- Hodnota metriky Prevádzková marža spoločnosti Bilfinger SE je 2.36%
- Hodnota metriky Prevádzková marža spoločnosti Vicon je 2.36%
- Hodnota metriky Prevádzková marža spoločnosti Anacle Systems je 2.36%
- Hodnota metriky Prevádzková marža spoločnosti K&S je 2.36%
- Hodnota metriky Prevádzková marža spoločnosti NSK je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti China Yongda Automobiles Services je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti Knight Therapeutics je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti Eolus Vind AB (publ) je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti Ricoh je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti Megaport je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti CHS je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti CHS je 2.37%
- Hodnota metriky Prevádzková marža spoločnosti Muehlhan AG je 2.37%